Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BCRX
BIOCRYST PHARMACEUTICALS, INC.
NASDAQ
$10.17
▲ UP 2.52% (0.25)

KEY STATISTICS

Market Cap$2.59 B
52w High$11.22
52w Low$6.00
Dividend Yield—
Frequency—
P/E-6.78
Volume3.13M
Shares Out.254.16M

COMPANY

LEADERSHIP

Charles K. Gayer
CHIEF EXECUTIVE
Charles K. Gayer

COMPENSATION 2026

Salary$609,397
Stock Awards$3,358,230
Incentive Plan Pay$749,088
All Other Comp.$17,500
Total$9,627,868

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 4, 1994
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
435

PRICE TARGET

Target High$29.00
Target Low$14.00
Target Median$17.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$165.38M
NOV
2
MON

PRICE

$10.17 ▲ UP 2.52% (+$0.25)
$9.90$10.05$10.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.17

About BioCryst Pharmaceuticals, Inc.

https://www.biocryst.com ↗

BioCryst Pharmaceuticals, founded in 1986 in Durham, NC, develops oral small-molecule medicines, including influenza treatments and therapies for hereditary angioedema and other diseases, through collaborations with various biotech and government ...

INDUSTRY

Biotechnology

A PRODUCT BIOCRYST PHARMACEUTICALS, INC. IS KNOWN FOR

ORLADEYO® (berotralstat)
ORLADEYO® (berotralstat)

ORLADEYO, BioCryst’s oral, once-daily medication for HAE attack prevention in patients 12 and older, offers a convenient alternative to injections and is being expanded for younger pediatric use.

COMPETITORS

COMPETITOR
IONS COMPARE
KA KALV COMPARE
PHAR COMPARE
PHVS COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$157.74M — $151.4M ▼$157.51M ▲
License and Other Revenues— — — $60.74M
License— $708K $3.02M ▲—
Collaborative and Other Research and Development$1.66M — $2M ▲—

ETFS HOLDING THIS STOCK

ETFS HOLDING
158
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.86% · 10.1M
VTI
0.00% · 8.1M
XSU.TO
0.07% · 6.0M
VETS
0.57% · 1.6M
PBE
2.63% · 1.3M
SCHA
0.05% · 1.2M
JSMD
1.00% · 1.1M
DFMC
0.10% · 831.9K
FESM
0.12% · 797.5K
PSC
0.24% · 664.4K
FYC
0.38% · 559.1K
LABU
0.63% · 370.4K
DX2D.DE
0.89% · 323.4K
SBIO
1.29% · 313.5K
GSSC
0.23% · 259.0K
BBP
1.40% · 168.3K
RSSL
0.07% · 111.1K
ISMD
0.20% · 68.6K
BBSC
0.09% · 68.1K
ETLI.DE
2.63% · 67.7K
TPSC
0.16% · 63.5K
SILX
2.47% · 60.5K
GERM
3.70% · 45.4K
FLQS
0.25% · 12.2K
RFLR
0.12% · 11.2K
URTY
0.03% · 9.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.68%
HOLDERS
454
TOP 12 OF 454 · RANKED BY POSITION SIZE
Blackrock, Inc.
23.9M sh · $238.93M
Vanguard Group Inc
22.3M sh · $173.73M
Blackrock Inc.
20.0M sh · $123.33M
Ra Capital Management, L.P.
15.8M sh · $158.27M
State Street Corp
15.2M sh · $151.91M
Deerfield Management Company, L.P. (Series C)
15.1M sh · $150.96M
Tcg Crossover Management, LLC
11.0M sh · $110.21M
Perceptive Advisors LLC
10.3M sh · $103.09M
Kynam Capital Management, LP
9.4M sh · $71.27M
Janus Henderson Group Plc
8.9M sh · $84.85M
Vestal Point Capital, LP
8.3M sh · $83M
Two Sigma Investments, LP
6.8M sh · $67.75M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2025-11-13
 Josh Gottheimer
Josh Gottheimer
Purchase
2023-10-16

INSIDER TRADES

★
DIRECTOR
Galson Steven K
Purchase · 33.5K shares
2026-06-11
★
DIRECTOR
LEVIN ALAN G
Purchase · 15.3K shares
2026-06-11
★
DIRECTOR
Stonehouse Jon P
Purchase · 15.3K shares
2026-06-11
★
DIRECTOR
Milne Jill C.
Purchase · 33.5K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
BUY 2
MARKET OUTPERFORM 2
OVERWEIGHT 1
EQUAL WEIGHT 1
8 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM RBC Capital OUTPERFORM HC Wainwright & Co. BUY Cantor Fitzgerald OVERWEIGHT Citizens MARKET OUTPERFORM Needham BUY Barclays EQUAL WEIGHT JMP Securities MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
SYRE$86.00COMPARE
PHVS$34.75COMPARE
TRVI$16.68COMPARE
ZYME$30.71COMPARE
STOK$30.18COMPARE
NTLA$12.54COMPARE
MAZE$26.25COMPARE
WVE$4.75COMPARE